Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixabepilone versus paclitaxel or doxorubicin in previously treated advanced endometrial cancer
RBR-7spw98Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in endometrial cancer (EC) comparing Ixabepilone with Active control: paclitaxel or doxorubicin (2 arms). Started Mar 2010; status: recruiting.
02
Drugs
ixabepilonepaclitaxeldoxorubicin
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on RBR-7spw98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-7spw98.